ArticleGut and liver2023
Clinical Significance of Epstein-Barr Virus and
Article in Gut and liver, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Prognostic Implication of EBV Infection in Gastric Carcinomas: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Multifaceted roles of chemokines in gastric cancer: From tumor microenvironment modulation to therapeutic targeting (Review).Oncology letters · 2026Review
- Mastering gastric endoscopic submucosal dissection: A learning curve analysis of over 100 consecutive cases performed by Western endoscopist.World journal of gastrointestinal endoscopy · 2026Article
- Gut microbiota interactions with the immunomodulatory role of 25-hydroxyvitamin D in children with infectious mononucleosis.Frontiers in medicine · 2026Article
- Retrospective Review of Children Hospitalized for Epstein-Barr Virus-Related Infectious Mononucleosis.Pathogens (Basel, Switzerland) · 2025Article
- Impact of gastric neoplasms location on clinical outcome of patients treated by endoscopic submucosal dissection.World journal of gastrointestinal endoscopy · 2025Article
- Distribution and Clinical Impact ofAntibiotics (Basel, Switzerland) · 2025Article
- Comparison of clinicopathological parameters with the presence of Epstein-Barr virus and the absence of DNA mismatch repair proteins in gastric adenocarcinomas.Asian biomedicine : research, reviews and news · 2025Article
- Association ofFrontiers in medicine · 2025Review
- Therapeutic opportunities in EBV-positive gastric cancer subtypes.Therapeutic advances in medical oncology · 2025Review
- Construction and evaluation of a polygenic hazard score for prognostic assessment in localized gastric cancer.Fundamental research · 2024Article
- EBV-Associated Gastric Cancer; An In Situ Hybridization Assay on Tissue Microarray: A Multi-Region Study from Four Major Provinces of Iran.Archives of Iranian medicine · 2024Article
- NJournal of translational internal medicine · 2024Article
- The role of fungi in the diagnosis of colorectal cancer.Mycology · 2024Review
- The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape.Frontiers in immunology · 2024Review
- Clinical outcomes of Epstein-Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- Review
- Review
- Inflammation and Digestive Cancer.International journal of molecular sciences · 2023Review
- Clinical Relevance ofGut and liver · 2023Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Epstein-Barr virus (EBV) and Methods: Overall, 956 patients who underwent surgery for gastric cancer between September 2014 and August 2015 were eligible and divided into groups, according to GCLS morphology, EBV infection, and HP infection. Clinicopathologic characteristics and oncologic outcomes were analyzed retrospectively. Results: EBV and HP coinfection was significantly associated with male sex, proximal location, GCLS morphology, and equivocal p53 expression (p<0.001). Multivariate analysis revealed that EBV infection alone (hazard ratio [HR], 0.362; 95% CI, 0.131 to 0.996; p=0.049) and lower third location (HR, 0.624; 95% CI, 0.413 to 0.943; p=0.025) were inversely correlated with overall survival. During median follow-up period of 72 months, overall survival rate was not significantly different between the EBV and HP coinfection group and others (97.6% vs 86.8%; log-rank p=0.144). In non-GCLS patients (n=920), overall survival rate was not significantly different between the EBV infection group and others (96.9% vs 86.4%; log-rank p=0.126). Conclusions: EBV and HP coinfection is not an independent prognostic factor for gastric cancer. EBV infection status, regardless of HP infection, affects the clinicopathologic features of all types of gastric cancer. However, it does not lead to a significant difference in overall survival of non-GCLS patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.